627536-09-8
中文名稱
SD-208
英文名稱
SD-208
CAS
627536-09-8
分子式
C17H10ClFN6
分子量
352.753
MOL 文件
627536-09-8.mol
更新日期
2024/12/23 17:39:05
627536-09-8 結(jié)構(gòu)式
基本信息
中文別名
TGF-ΒRI抑制劑(ALK5抑制劑)(SD-208)2-(5-氯-2-氟苯基)-N-4-吡啶基-4-蝶啶胺
2-(5-氯-2-氟苯基)-4-[(4-吡啶基)氨基]蝶啶
2-(5-氯-2-氟苯基)-N-(吡啶-4-基)蝶啶-4-胺
英文別名
SD-208CS-2295
SCI 208
SD-208 10MG
SD-208 (SD 208
ALK5 Inhibitor V
SD-208 USP/EP/BP
TGF-β RI Kinase Inhibitor V
SD-208
SD 208
SD208
SCI 208
SD 208
SD208
TGF-Β RI KINASE INHIBITOR V
所屬類別
生物化工:TGF-beta/Smad 抑制劑常見問題列表
生物活性
SD-208是一種選擇性TGF-βRI (ALK5)抑制劑,with IC50為48 nM,選擇性比TGF-βRII高100多倍。體外研究
SD-208 inhibits the cell growth and constitutive and TGF-beta-evoked migration and invasion, and enhances immunogenicity in murine SMA-560 and human LN-308 glioma cells. SD-208 blocka TGF-beta-induced phosphorylation of the receptor-associated Smads, Smad2 and Smad3, and stimulates epithelial-to-mesenchymal transdifferentiation, migration, and invasiveness into Matrigel in vitro. SD-208 also abolishes the promoting effect of TGF-β on neointimal smooth muscle-like cell (SMLC) proliferation and migration in vitro.體內(nèi)研究
SD-208 (1 mg/mL, p.o.) significantly prolongs the median survival of SMA-560 glioma-bearing mice. In syngeneic 129S1 mice, SD-208 (60 mg/kg/d, p.o.) inhibits primary R3T tumor growth, and reduces the number and the size of lung metastases. In the murine aortic allograft model, SD-208 effectively reduces the formation of intimal hyperplasia of transplant arteriosclerosis (TA).靶點(diǎn)
Target | Value |
TGF-βRI (ALK5)
(Cell-free assay) | 48 nM |
體外研究
在小鼠SMA-560和人SMA-560膠質(zhì)瘤細(xì)胞中,SD-208抑制細(xì)胞生長(zhǎng),組成,和TGF-β誘發(fā)的遷移和浸潤(rùn),并增強(qiáng)免疫原性。在體外,SD-208阻斷TGF-β誘導(dǎo)的受體相關(guān)的Smads,Smad2和Smad3磷酸化,并刺激上皮細(xì)胞到間葉細(xì)胞的分化轉(zhuǎn)化,遷移,以及侵襲到基底膜。在體外,SD-208也會(huì)廢除TGF-β對(duì)新生內(nèi)膜平滑肌樣細(xì)胞(SMLC)增殖和遷移的保護(hù)作用。
體內(nèi)研究
SD-208 (1 mg/mL, p.o.)顯著延長(zhǎng)負(fù)荷SMA-560膠質(zhì)瘤小鼠的中值存活率。在同源129S1小鼠體內(nèi),SD-208 (60 mg/kg/d, p.o.)抑制初級(jí)R3T腫瘤生長(zhǎng),并減少肺轉(zhuǎn)移的數(shù)量和大小。在小鼠大動(dòng)脈同種移植模型中,SD-208有效減少移植動(dòng)脈硬化(TA)內(nèi)膜增生的形成。